



**Center for Vaccine Ethics & Policy (CVEP)**  
**Vaccines and Global Health: The Week in Review**  
**07 February 2026 :: Issue 831**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

## ***Milestones, Perspectives***

.....  
.....

### ***Editor's Note:***

The WHO EB meeting concluded on Friday, a day earlier than scheduled. No WHO summary of the overall EB meeting was identified as we completed this edition.

## **WHO – 158th session of the Executive Board**

**2–7 February 2026**

Main Documents *[selected]*

[EB158/1](#)

Provisional agenda

[EB158/1 \(annotated\)](#)

Provisional agenda (annotated)

## **WHO Director-General's closing remarks at the 158th session of the Executive Board – 6 February 2026**

*[Excerpt]*

...Thank you to all Member States for your engagement, which reflects the value you place on WHO and its work.

From NCDs and mental health to TB, rare diseases, neglected tropical diseases, AMR, UHC, polio, emergencies and more, you have highlighted some of the many issues that transcend national borders and that require a coordinated international response.

Thank you also for the attention you have given to governance reform. As I said at the beginning of the week, a more efficient and effective WHO means reform to both the Secretariat and the governance that Member States provide – and thank you again to Secretary Blair.

Thank you for the guidance you have given, the consensus you have forged, and the commitment you have demonstrated to WHO.

Your Secretariat remains fully committed to following your guidance, and supporting all Member States.

Our prioritization and realignment has helped to give us clarity – clarity about where WHO has the greatest comparative advantage and adds the greatest value.

We are now moving forward as a leaner Secretariat, focused on leveraging that comparative advantage and delivering that value, with clarity for our future...

.....





Session recording available [here](#) under "IGWG Briefing, 04/02/2026"

**WHO Director-General's opening remarks at the Intergovernmental Working Group on the WHO Pandemic Agreement (IGWG) briefing to the 158th session of the WHO Executive Board – 4 February 2026**

*[Excerpt]*

...My sincere appreciation to the co-chairs and the Bureau for their steady leadership, and to all IGWG members for the dedication they have brought to this work.

You have developed the space for dialogue, prepared the technical groundwork and supported Member States through each stage of this negotiation.

**Needless to say, the IGWG meeting next week is a make-or-break moment to build convergence.**

It is an opportunity to narrow gaps, clarify expectations and move toward shared understanding on the key issues that remain. Progress next week will be essential for maintaining momentum.

As you know, the World Health Assembly has given the IGWG a clear mandate. The Pandemic Agreement has been adopted, and the task now is to complete the work needed to operationalize it. Without the PABS Annex, as you know, the Agreement is not fully ready for signature, ratification and implementation.

**The deadline is absolute. This year's World Health Assembly must receive a text that Member States can consider and act upon.** There is no scope for delay – I hope – because the next pandemic will not wait.

You, the Member States, demonstrated last year that progress is possible, even under pressure.

**You reached agreement on the core instrument itself, including Article 12,** which sets out many of the elements that guide your work today.

You can do it again. The Secretariat stands ready to support you at every stage of the process... The world is watching, so my message to all Member States is: let's get this done. I am very confident you will.

.....

**Fifth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement**

9 – 14 February 2026

Hybrid, Geneva, Switzerland

[A/IGWG/5/1](#)

Provisional agenda

[A/IGWG/5/2](#)

Draft programme of work

[Draft PABS Annex text](#)

Webcast of selected IGG sessions and other documentation [here](#).

**IGWG Meeting timeline**

- 9–10 July 2025: First meeting of the IGWG
- 15–19 September 2025: Second meeting of the IGWG
- Week of 6–10 October 2025: Informal meetings of the IGWG
- 3–7 November 2025: Third meeting of the IGWG

- 24–25 November 2025: Informal dialogues of the IGWG
- 1–5 December 2025: Fourth meeting of the IGWG
- **9–14 February 2026: Fifth meeting of the IGWG**
- 23–28 March 2026: Sixth meeting of the IGWG
- July 2026 (tbc): Seventh meeting of the IGWG
- September 2026 (tbc): Eighth meeting of the IGWG

.....

## **Pandemic Preparedness**

### **Korea to run landmark pandemic simulation exercise to strengthen outbreak readiness**

5 February 2026, SEOUL, Republic of Korea —

**A pioneering fictional pandemic simulation exercise will be held in the Republic of Korea by the Korean Government, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI)** to explore opportunities to strengthen Korean readiness to rapidly develop and test new vaccines in the event of a future pandemic threat.

**The tabletop exercise is the first of its kind to be held in Korea and the region** with the Government's Ministry of Food Drug & Safety (MFDS), a World Health Organization-listed regulatory authority, and the world-leading Korea Disease Control and Prevention Agency (KDCA).

**The meeting will bring together several expert organisations based in Korea working across pandemic preparedness**—from threat detection through to licensure of life-saving medical tools—to simulate a realistic scenario imagining that a never-seen-before fictitious deadly virus is spreading fast and infecting people.

Using skills, knowledge and plans developed during COVID-19 and in the years since the pandemic, attendees will be invited to discuss how they would work together across research and development, manufacturing and other parts of the vaccine chain to improve readiness and identify bottlenecks ahead of a potential health emergency.

**The exercise will enhance Korea's real-world response readiness by strengthening the scientific, regulatory and manufacturing capabilities needed to rapidly develop new vaccines against emerging epidemic and pandemic threats...**

.....

.....

## **Health Emergencies and Crisis Settings**

### **WHO launches 2026 appeal to help millions of people in health emergencies and crisis settings**

3 February 2026 The World Health Organization (WHO) today launched its 2026 global appeal to ensure that millions of people living in humanitarian crises and conflicts can access health care. In 2025, WHO and partners supported 30 million people funded through its annual emergency appeal. These resources helped deliver life-saving vaccination to 5.3 million children, enabled 53 million health consultations, supported more than 8000 health facilities, and facilitated the deployment of 1370 mobile clinics.

**The 2026 appeal seeks nearly US\$ 1 billion to respond to 36 emergencies worldwide, including 14 Grade 3 emergencies** requiring the highest level of organizational response. These emergencies span sudden-onset and protracted humanitarian crises where health needs are critical.

“This appeal is a call to stand with people living through conflict, displacement and disaster – to give them not just services, but the confidence that the world has not turned its back on them,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “It is not charity. It is a strategic investment in health and security. In fact, access to health care restores dignity, stabilizes communities and offers a pathway toward recovery.”...

#### **WHO and partners’ emergency response actions include**

- keeping essential health facilities operational;
- delivering emergency medical supplies and trauma care;
- preventing and responding to outbreaks;
- **restoring routine immunization; and**
- ensuring access to sexual and reproductive, maternal and child health services in fragile and conflict-affected settings...

.....  
.....

## **Cholera**

### **Preventive cholera vaccination resumes as global supply reaches critical milestone**

GENEVA/NEW YORK, 4 February 2026 – **Global cholera vaccine supply has now increased to a level sufficient to allow the resumption of life-saving preventive campaigns for the first time in over three years**, Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO) announced today.

**Mozambique is the first country to restart preventive vaccination**, following the halt in 2022 caused by the global surge in cholera cases that drove up demand and led to shortages of oral cholera vaccine (OCV) stocks.

**The preventive vaccination campaign begins amid an ongoing cholera outbreak and the aftermath of floods that affected more than 700 000 people and displaced many.** The floods disrupted health systems and damaged water systems, further increasing the risk of waterborne diseases such as cholera.

“Global vaccine shortages forced us into a cycle of reacting to cholera outbreaks instead of preventing them. We are now in a stronger position to break that cycle. **I thank EUBiologics, currently the only manufacturer producing cholera vaccines at the scale needed for mass vaccination campaigns, for its efforts, and urge others to enter this vital space. These vaccines will save lives,**” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

**A first allocation of 20 million doses is being deployed for preventive campaigns. Of these, 3.6 million doses were delivered to Mozambique; 6.1 million to the Democratic Republic of the Congo that is also experiencing significant outbreaks; and 10.3 million doses are planned for delivery to Bangladesh.**

Following sustained efforts by global agencies, manufacturers and partners, **annual global supply of OCV has doubled from 35 million doses in 2022 to nearly 70 million doses in 2025. The doses are being financed by Gavi, and procured and delivered to countries by UNICEF.**

"The multi-year surge in cholera cases and resulting unprecedented demand for vaccines were stark reminders that sustainable, accessible vaccine supply is a global public good – and the world cannot afford complacency," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. "We are grateful to our partners and manufacturers, particularly EUBiologics, for the collaboration that has made the resumption of these essential preventive campaigns possible, and to Gavi's donors, whose support enables us to finance the global OCV stockpile and life-saving outbreak and preventive campaigns."

"For the first time in years, this increase in vaccines will allow us to better prevent large-scale cholera emergencies," said **Catherine Russell, UNICEF Executive Director**. **"Resuming preventive cholera vaccination will protect children and help stop this highly contagious disease in its tracks. But it must go hand in hand with other efforts, including better access to safe water and basic sanitation."**

The three countries were chosen based **on allocation criteria set out by the Global Task Force for Cholera Control (GTCC), a partnership of over 50 organizations, to ensure cholera vaccines for preventive campaigns are distributed systematically, equitably and transparently...**

.....

### [Multi-country outbreak of cholera, epidemiological update #33 -27 January 2026](#)

#### *Overview*

From 1 January to 28 December 2025, a cumulative total of 614 828 cholera cases and 7598 deaths were reported from 33 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the Western Pacific Region. No cases were reported from the European Region during this period.

In December 2025 (epidemiological weeks 49 to 52) a total of 17 327 new cholera and acute watery diarrhoea (AWD) cases were reported from 16 countries across three WHO regions, showing a 25% decrease from November. In this period, 137 cholera-related deaths were reported globally, a 16% decrease from the previous month.

## Multi-country outbreak of cholera



Epidemiological Update n. 33, published 27 January 2026<sup>1</sup>

Cases – 614 828  
Since Jan. 2025

Deaths – 7 598  
Since Jan. 2025

Countries affected – 33  
Since Jan. 2025

Population at risk  
1 billion

Global risk –  
Very high

*[OCV, vaccines, immunization not referenced in report]*

.....

### [Quantifying the contribution of Oral Cholera Vaccine to global health through tech-transfers and WHO stockpile deployment since its inception: a modeling study](#)

Jung-Seok Lee, Wongyeong Choi, Florian Marks, John D. Clemens, Jerome H. Kim, Julia Lynch  
PREPRINT - medRxiv 2026.02.02.26345439; doi:  
<https://doi.org/10.64898/2026.02.02.26345439>

... *What this study adds*

We evaluated the actual impact of deployed doses on cholera morbidity, mortality, and economic burden since the inception of the OCV stockpile in 2013. Our model further investigated what the impact of OCV would have been with no delays in implementation and no supply shortage by incorporating the detailed daily shipment data which included the number of OCV doses and dates for request, decision (approval), and delivery. The current analyses show that from 2013 to 2025, both reactive and preventive vaccination campaigns implemented through the global OCV stockpile averted more than 6.7 million DALYs, 146,013 deaths, and US\$1.05 billion of the economic burden in 37 recipient countries. Our model demonstrates that vaccination impact would be further enhanced if there were no delays in the implementation of campaigns and if there were no shortage of OCV supplies.

How this study might affect research, practice or policy

To our knowledge, no previous study has assessed the holistic contribution of the global OCV stockpile and investigated the optimal outcomes which may have been partially lost due to programmatic and logistical challenges. Since its inception, the impact of the OCV stockpile on global health has been substantial, and the additional benefits are expected if cholera vaccines can be deployed on time and if there is no supply constraint. In particular, the benefits induced by improving timing of vaccination does not necessarily come with additional costs associated with vaccine supplies which are known to be the major cost driver. In addition, because all stockpile recipient countries are currently required to implement a single-dose OCV campaign due to the shortage of OCVs, the continuous support for a two-dose vaccination campaign would bring much larger benefits than the single-dose vaccination scheme given a single-dose vaccination with the OCV is known to be much less efficacious among young children.

Considering ongoing cholera outbreaks across multiple regions and other cholera vaccine candidates in development, our findings can be used not only to help provide guidance for the decision-making process on the future OCV stockpile deployment, but also to understand the optimal usage and potential impacts of multiple cholera vaccines which can be administered by different strategies in the future.



## Polio – PHEIC

[Polio this week](#) [04 Feb 2026]

*Headlines [Selected]*

**:: WHO Executive Board signals renewed global unity to finish polio eradication**

**:: SAGE Polio Working Group reviews path to the endgame — from vaccine strategy to post-eradication planning**

This week, the Strategic Advisory Group of Experts on Immunization Polio Working Group convened to take stock of progress toward eradication and to examine the critical decisions shaping the polio endgame. Discussions covered programme performance and governance, planning for eventual bivalent OPV cessation, advances in novel OPV and next-generation IPV manufacturing, and how evolving vaccine strategies can best protect children while safeguarding a polio-free future. The group also began formulating recommendations on the optimal role of IPV and bOPV in routine immunization as the world prepares for the final phase of eradication. Outcomes from the meeting will inform deliberations by the full SAGE on 9-12 March.

### ***Summary of new polioviruses this week:***

:: Afghanistan: three WPV1 cases and four WPV1-positive environmental samples

:: Pakistan: three WPV1-positive environmental samples

:: Benin: two cVDPV2-positive environmental samples



:: Chad: two cVDPV2 cases  
:: DR Congo: one cVDPV2 case

.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)  
:: [WHO](#)  
:: [U.S. Immunization and Public Health Governance/Policy/Funding](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)  
:: [Think Tanks](#)  
:: [Public Consultations/Call for Inputs/Call for Papers](#)

.....  
.....

**WHO & Regional Offices** [07 Feb 2026]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

5 February 2026 *Statement*

**[Over four million girls still at risk of female genital mutilation: UN leaders call for sustained commitment and investment to end FGM](#)**

4 February 2026 *News release*

**[Preventive cholera vaccination resumes as global supply reaches critical milestone](#)**

3 February 2026 *Joint News Release*

**[Four in ten cancer cases could be prevented globally](#)**

3 February 2026 *News release*

**[WHO launches 2026 appeal to help millions of people in health emergencies and crisis settings](#)**

3 February 2026 *Statement*

**[Joint statement on the renewed Quadripartite Memorandum of Understanding regarding cooperation on One Health until 2030](#)**

2 February 2026 *Statement*

**[Six years after COVID-19's global alarm: Is the world better prepared for the next pandemic?](#)**

2 February 2026 *Departmental update*

**[New customs classification for vaccines to strengthen emergency preparedness](#)**

.....

**WHO Vaccines and Immunization [IVB]**

[https://www.who.int/health-topics/vaccines-and-immunization#tab=tab\\_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)

*News*

*No new digest content identified.*



.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: 06 February 2026

#### **Intensifying emergency response to Mozambique flooding disaster**

:: 04 February 2026

#### **From villages to markets: Burkina Faso leads the way in cervical cancer elimination**

:: 03 February 2026

#### **Sierra Leone transforms lives through expanded cervical cancer care**

### **WHO Region of the Americas PAHO**

:: 6 Feb 2026

#### **PAHO launches virtual reality laboratory to build capacity in respiratory virus surveillance in the Americas**

Washington, D.C., February 6, 2026 (PAHO) — The Pan American Health Organization (PAHO) has launched a virtual reality (VR) platform designed to build capacity and strengthen preparedness across public health laboratories in the Americas for the surveillance of influenza and other pathogens with epidemic potential. This immersive digital tool was...

:: 4 Feb 2026

#### **PAHO issues epidemiological alert amid continued measles transmission in the Americas and urges strengthened vaccination and surveillance**

Washington, D.C., February 4, 2026 (PAHO) — The Pan American Health Organization (PAHO) has issued a new epidemiological alert on measles for the Region of the Americas, calling on countries to intensify epidemiological surveillance, vaccination, and rapid outbreak response activities to interrupt transmission and protect vulnerable populations....

:: 3 Feb 2026

#### **PAHO urges strengthening cervical cancer prevention and care to advance toward its elimination**

In the Region, 24 countries have adopted the single-dose schedule for the HPV vaccine, but greater efforts are needed to expand screening and treatment. Washington, D.C., February 3, 2026 (PAHO) – On World Cancer Day (February 4), the Pan American Health Organization (PAHO) called on countries to accelerate efforts to achieve cervical cancer 2030...

### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

### **WHO European Region EURO**

:: 6 February 2026 *Media release*

#### **Ukraine: WHO seeks US\$ 42 million in 2026 to protect health care as war enters its fifth year**

### **WHO Eastern Mediterranean Region EMRO**

:: 4 February 2026

#### **Reaching the unreachable: accelerating onchocerciasis elimination in Yemen**

### **WHO Western Pacific Region**

:: 3 February 2026 *Media release*

#### **KOICA reaffirms commitment with MHMS and WHO to promote and protect maternal and newborn h...**

.....

### **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

**[6 February 2026 | Nipah virus infection - Bangladesh](#)**

.....

### **Weekly Epidemiological Record**

Vol. 101, No. 4-6 6 February 2026

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Strengthening medicine procurement and supply chain management for neglected tropical diseases in 2025: achievements, challenges and way forward

:: Global update on implementation of preventive chemotherapy against neglected

.....

### **New WHO Publications**

<https://www.who.int/publications>

*Selected*

6 February 2026

**[Global update on implementation of preventive chemotherapy against neglected tropical diseases in 2024](#)**

6 February 2026

**[Strengthening medicine procurement and supply chain management for neglected tropical diseases in 2025:...](#)**

.....

.....

.....

### **Africa**

**Africa CDC** [07 Feb 2026]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

**[Africa CDC Opens First Medical Supplies Warehouse to Boost Public Health Emergency Response](#)**

Addis Ababa, Ethiopia – 02 February 2026 – The Africa Centres for Disease Control and Prevention (Africa CDC) has opened its first dedicated warehouse, marking a major milestone in strengthening the continent's capacity to procure, store and rapidly dispatch critical medical supplies during public health emergencies.

The 1,000-square-metre warehouse, located at the Africa CDC headquarters in Addis Ababa, is equipped with cold storage systems to safely store medical and other essential supplies. Africa CDC Deputy Director General Dr Raji Tajudeen said the facility significantly enhances the agency's operational readiness. "We now have what it takes to respond in the most efficient and timely manner to disease outbreaks," he said, noting that rapid access to medical products can mean the difference between containment and escalation.

Funded by the Mastercard Foundation through mpox emergency response funding, the facility was developed with the support of the United Nations World Food Programme (WFP), which provided end-to-end supply chain expertise – from design and engineering supervision to logistics, cold storage systems and safety compliance...

*Communiqué*

### **Communiqué: Continental Immunization Strategy Adoption**

3 February 2026

... Africa CDC, through the Immunization Unit within the Primary Health Care Center, is stepping up to support African Union Member States' immunization agendas and is developing its Continental Immunization Strategy (CIS), providing a pragmatic, time-bound pathway to strengthen immunization systems across Africa by anchoring vaccination firmly within resilient, epidemic-ready Primary Health Care (PHC) and health-security architectures. The CIS is designed to close equity gaps, reach zero-dose and under-immunized populations, and sustain life-course immunization while advancing the Addis Declaration on Immunization (ADI) and Immunization Agenda 2030 (IA2030) goals.

PDF: <https://africacdc.org/wp-content/uploads/2026/02/Communiqué-CONTINENTAL-IMMUNIZATION-STRATEGY-ADOPTION.pdf>

### **Financing Africa's Health Security and Sovereignty**

*A Health Financing Reform Handbook for African Union Member States.*

2 February 2026

.....  
.....

### **China – CDC+**

**National Health Commission of the People's Republic of China** [07 Feb 2026]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [07 Feb 2026]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

**CCDC Weekly Reports: Current Volume (7)**

**2026-02-06 / No. 6**

[View PDF of this issue](#)

*No new digest content identified.*

.....  
.....

## Europe

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*Surveillance and monitoring*

#### **Communicable disease threats report, 31 January - 6 February 2026, week 6**

6 Feb 2026

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 January - 6 February 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2 variant classification, Bacillus cereus toxin in infant formula, mass gathering monitoring, mpox, nipah virus, and Middle East respiratory virus syndrome.

*Surveillance and monitoring*

#### **Monthly measles and rubella monitoring report - December 2025**

3 Feb 2026

This report provides an overview of measles and rubella cases reported to ECDC through The European Surveillance System (TESSy).

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

.....  
.....

## India

### **National Centre for Disease Control**

*Directorate General of Health Services, Ministry of Health & Family Welfare*

*Announcements*

*No new digest content identified.*

.....  
.....  
.....

### **U.S. Immunization and Public Health Governance/Policy/Funding**

*Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive*

### **Executive Branch - White House, State, HHS, FDA, CDC+**

#### **White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations*

*No new digest content identified.*

**UNAIDS strongly welcomes bold, new US funding package for HIV**

GENEVA, 5 February 2026—UNAIDS welcomes the signing into law of a bipartisan US\$ 5.88 billion spending package that reinforces the continued commitment and leadership of the United States in the global response to HIV.

US President Donald Trump signed the consolidated spending package into law on 3 February 2026 which allocates US\$ 4.6 billion to bilateral HIV support through the America First Global Health Strategy, US\$ 1.25 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria and US\$ 45 million to UNAIDS...

## **Department of State**

[Press Releases](#) - *Selected*

*Media Note*

### **[Delivering Additional Humanitarian Support Directly to the Cuban People](#)**

February 5, 2026

*Press Statement*

### **[Sudan Humanitarian Fund Call to Action Event](#)**

February 4, 2026

## **HHS**

[Press Room](#) - *Selected*

*No new digest content identified.*

**NIH** [to 07 Feb 2026]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

## **FDA**

[Press Announcements](#)

*FDA News Releases*

*No new digest content identified.*

## **FDA CBER**

[What's New for Biologics](#)

*No new digest content identified.*

## **FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]**

[Advisory Committee Calendar](#)

***No future meetings posted.***

## **FDA Pediatric Advisory Committee Meeting**

[Advisory Committee Calendar](#)

***No future meetings posted.***

## **CDC**

<http://www.cdc.gov/media/index.html>

*Latest News - Selected*

*No new digest content identified.*

## **CDC – Immunization Safety Office (ISO)**

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

*No new digest content identified.*

## **ACIP**

### **2026 Meetings Schedule** *[no agenda content posted]*

- February 25-26
- June 24-25
- October 21-22

#### **Leading Public Health Groups Seek Expedited Injunctive Relief Against Immunization Schedule Changes, Upcoming ACIP Meeting; Hearing Scheduled Friday, February 13**

January 13, 2026

A group of medical professional societies, led by the American Academy of Pediatrics (AAP) and including the American Public Health Association (APHA), seek to enjoin the upcoming February 25-26 ACIP meeting and vacate recent changes to the pediatric immunization schedule. A hearing on plaintiffs' preliminary injunction is scheduled for Friday, February 13.

## **National Vaccine Advisory Committee (NVAC)**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

## **Advisory Commission on Childhood Vaccines (ACCV)**

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

*No new digest content identified.*

## **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

*No new digest content identified.*

:::::::

## **NSF**

*News*

*No new digest content identified.*

:::::::

## **U.S. Congress**

### **House of Representatives**

*No new digest content identified.*

### **U.S. Senate**

#### ***Senate Health, Education, Labor, and Pensions (HELP) Committee***

*No new digest content identified.*

:::::::

## **Supreme Court, Federal & Appellate Courts**

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

*No new digest content identified.*



## **U.S. Medical, Professional Societies; Health Organizations**

*This inventory is evolving and may not capture all instances of relevant comment and analysis.*

### **American Academy of Family Physicians (AAFP)**

<https://www.aafp.org/news/media-center.html>

(Accessed 07 Feb 2026)

*No new digest content identified.*

### **American Academy of Pediatrics (AAP)**

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 07 Feb 2026)

*News*

*No new digest content identified.*

### **American College of Physicians (ACP)**

<https://www.acponline.org/more-acp-news>

(Accessed 07 Feb 2026)

*ACP News*

**[Vaccine access tops the list of ACP advocacy priorities in 2026](#)**

02/02/26    *ACP Advocate*

### **America's Health Insurance Plans (AHIP)**

<https://www.ahip.org/news>

(Accessed 07 Feb 2026)

*News*

*No new digest content identified.*

### **American Geriatrics Society (AGS)**

<https://www.americangeriatrics.org/media-center>

(Accessed 07 Feb 2026)

*Recent Press Releases*

*No new digest content identified.*

### **American Medical Association (AMA)**

<https://www.ama-assn.org/press-center>

(Accessed 07 Feb 2026)

*Press Releases*

Feb 3, 2026 · 1 MIN READ

**[AMA urges public to get vaccinated against measles as cases rise](#)**

*Statement attributable to: Sandra Adamson Fryhofer, MD, Trustee, American Medical Association*

"With measles cases on the rise – and the U.S. at real risk of losing its measles elimination status for the first time in 25 years—now is the time to make sure you and your family are vaccinated.



“Measles spreads very easily, often before people realize they’re sick, and it can lead to serious complications—including pneumonia, brain swelling, blindness, and even death. The MMR vaccine has protected our communities for decades, yet falling vaccination rates are driving today’s measles outbreaks, hospitalizations, and the first deaths in many years—largely among people who were not vaccinated.

“We urge you to talk with your doctor and make sure your family is protected. There is no cure for measles, but vaccination protects you, your loved ones, and those who are too young or medically unable to be vaccinated.”

### **American Osteopathic Association (AOA)**

<https://osteopathic.org/news/>

(Accessed 07 Feb 2026)

*Latest News*

*No new digest content identified.*

### **American Public Health Association (APHA)**

[https://www.apha.org/news-and-media/news-](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

[releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

(Accessed 07 Feb 2026)

*No new digest content identified.*

### **Infectious Diseases Society of America (IDSA)**

<https://www.idsociety.org/>

(Accessed 07 Feb 2026)

*News releases and statements*

*No new digest content identified.*

### **National Foundation for Infectious Diseases (NFID)**

<https://www.nfid.org/news-updates/>

(Accessed 07 Feb 2026)

*News and Updates*

February 5, 2026

#### **[News Round-Up: Vaccines, Measles, Flu, and COVID-19](#)**

News and expert insights on COVID-19, influenza, measles, outbreak preparedness, and vaccine policy—including growing concerns about data gaps, divergent immunization recommendations, and the real-world consequences for public health

### **National Medical Association (NMA)**

<https://nmanet.org/blog/>

(Accessed 07 Feb 2026)

*Latest News*

*No new digest content identified.*

### **Pediatric Infectious Diseases Society (PIDS)**

<https://pids.org/news-announcements/>

(Accessed 07 Feb 2026)

*News & Announcements*  
*No new digest content identified.*

### **Society for Healthcare Epidemiology of America (SHEA)**

<https://shea-online.org/news/>

(Accessed 07 Feb 2026)

*No new digest content identified.*

### **Society for Maternal-Fetal Medicine (SMFM)**

<https://www.smfm.org/>

(Accessed 07 Feb 2026)

*News*

*No new digest content identified.*

.....  
.....

### **Civil Society – Individuals, Organizations, Institutions [Selected]**

.....

#### **Kaiser Family Foundation/KFF [07 Feb 2026]**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

#### **Global Health Funding in the FY 2026 National Security, Department of State and Related Programs (NSRP) Conference Bill & Explanatory Statement**

Feb 4, 2026 *Fact Sheet*

This budget summary provides an analysis of global health funding amounts provided in the National Security, Department of State and Related Programs (NSRP) Conference Bill & Explanatory Statement.

#### **Global Health Funding in the FY 2026 Labor, Health and Human Services, Education, and Related Agencies (Labor HHS) Conference Bill & Accompanying Report**

Feb 4, 2026 *Fact Sheet*

This budget summary provides an analysis of global health funding amounts provided in the FY 2026 Labor, Health and Human Services, Education, and Related Agencies (Labor HHS) conference bill and accompanying report.

#### **KFF Tracking Poll on Health Information and Trust: Trust in the CDC and Views of Federal Childhood Vaccine Schedule Changes**

Feb 6, 2026 *Poll Finding*

##### ***Key Takeaways***

- In the weeks following the Trump administration's announcement of changes to the recommended childhood vaccine schedule, **the public's trust in the CDC remains at its lowest point since the COVID-19 pandemic**, including a 9-percentage point drop among Democrats in recent months saying they trust the CDC for reliable vaccine information. Just over half (55%) of Democrats and fewer Republicans (43%) and independents (46%) now say they trust the agency for vaccine information. In addition, fewer than half of adults (44%) express confidence in U.S. federal health agencies to make recommendations about the childhood vaccine schedule.
- **Among the half of U.S. adults who report hearing about the recent changes to the childhood vaccine schedule, more say the changes will have a negative impact (54%) on children's health** than a positive one (26%). Partisans are split, with most Democrats who are

aware of the change saying it will have a negative impact on children (83%, or 63% of all Democrats), while Republicans are more likely to say it will have a positive impact (47% of Republicans who are aware of the change, or 34% of all Republicans). About one in five Republicans who are aware of the changes say they will negatively impact children's health and an additional one in five say they are not sure.

- **At least eight in ten U.S. adults across partisans and parents are confident – including about half who of adults who are “very confident” – in the safety of measles, mumps, and rubella (MMR) and polio vaccines,** two longstanding childhood vaccines that continue to be recommended as routine. Majorities of adults are also confident in the safety of two of the vaccines that are no longer universally recommended for children following recent changes, hepatitis B (70%) and flu (65%), though fewer are “very confident,” and views are somewhat divided along partisan lines. Fewer (48%) adults are confident in the safety of COVID-19 vaccines for children, including just one in four who are “very confident.” Partisan divisions are sharpest when it comes COVID-19 vaccines, with just three in ten Republicans compared to eight in ten Democrats expressing confidence that they are safe for children.

### **Poll: Trust and Confidence in the CDC Remain at Low Point After Changes to Recommended Childhood Vaccines; More Say the Changes Will Hurt than Help Children's Health**

Feb 6, 2026 *News Release*

In the weeks after the Trump administration reduced the number of recommended childhood vaccines for routine use, **the public's trust in the Centers for Disease Control and Prevention (CDC) remains at its lowest point**, a new [KFF Poll on Health Information and Trust](#) finds.


**Fewer than half (47%) now say that they trust the agency at least “a fair amount” to provide reliable vaccine information**, similar to the share who said the same in September, but down more than 10 percentage points since the beginning of the second Trump administration, and continuing a downward trend first measured during the COVID-19 pandemic.

The recent decline reflects falling confidence among Democrats. Slightly more than half (55%) of Democrats now say they trust the CDC on vaccines, down from 64% September. About 4 in 10 Republicans say they trust the CDC for vaccine information, similar to the share who said the same a few months ago and in 2023, but fewer than half as many as said they trusted the CDC on the coronavirus back in 2020.

**“Six years ago, 85% of Americans, and 90% of Republicans, trusted the CDC. Now less than half trust the CDC on vaccines,” KFF President and CEO Drew Altman said. “The wars over COVID, science, and vaccines have left the country without a trusted national voice on vaccines, and that trust will take time to restore.”**

## Trust in the CDC as an Information Source Has Declined Amid Changing Partisan Views

Percent who have a **great deal** or **fair amount** of trust in the U.S. Centers for Disease Control and Prevention (CDC) to provide reliable information about vaccines, COVID-19 vaccines, and coronavirus



Note: For September 2023 to present, question wording was "to provide reliable information about vaccines." For December 2020 to April 2022, question wording was "to provide reliable information about a COVID-19 vaccine." For March 2020 to September 2020, question wording was "to provide reliable information on coronavirus." See topline for full question wording.  
Source: KFF Health Tracking Polls

**KFF**

.....

### Vaccine Integrity Project – CIDRAP [to 07 Feb 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

*Announcements*

*No new digest content identified.*

.....

### Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>

[Selected]

### [Who's Really Behind the MAHA Movement?](#)

RFK Jr.'s recent removal of FDA warnings about dangerous autism therapies shows exactly who is funding the MAHA movement.

Feb 03, 2026

.....

.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)  
:: [WHO](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [07 Feb 2026]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**Gates Foundation** [07 Feb 2026]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

**[As Global Health Faces Its First Reversal in Progress in a Generation, Gates Foundation CEO Details a 20-Year Push to Save and Improve Lives](#)**

*Suzman says the setback shouldn't be permanent and lays out a roadmap to reclaim momentum and accelerate progress through 2045, even amid significant financial constraints globally*

SEATTLE (February 3, 2026) – Today, Gates Foundation CEO Mark Suzman released his [2026 Annual Letter](#), The road to 2045, warning that the recent reversal in global health progress raises urgent moral choices and outlining a 20-year agenda to accelerate impact as the foundation works toward completing its mission...

**CARB-X** [07 Feb 2026]

<https://carb-x.org/>

*News*

02.05.2026 |

**[CARB-X to support development of typhoid fever diagnostic from Chembio](#)**

CARB-X is awarding US\$1.8million to Chembio Diagnostic Systems, Inc. to develop a rapid point-of-care test for the detection of Immunoglobulin A (IgA) antibodies to diagnose acute infection of Salmonella enterica serovar Typhi.

**Chan Zuckerberg Initiative** [07 Feb 2026]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [07 Feb 2026]

<http://cepi.net/>

*CEPI News, Blog*

*Blog*

**[Strengthening biosecurity and biosafety oversight: CEPI publishes its first Biosecurity Policy](#)**

4 Feb 2026

Today marks an important milestone for CEPI's biosecurity program: the publication of CEPI's first-ever Biosecurity Policy and associated FAQ. This Policy, a key activity set out in CEPI's Biosecurity Strategy and Implementation Plan, is the result of extensive consultation, technical review, and engagement across sectors. It reflects a growing recognition that rapid advances in vaccine R&D and manufacturing, which are essential to realising the ambition of the 100 Days Mission, must be matched by clear, robust and responsible safeguards.

*News*

**[CEPI and Korea discuss future of AI-driven international health cooperation](#)**

3 Feb 2026

:: Seminar held at the National Assembly discussed strategic link between AI technology and Health ODA

:: CEPI expects Korea to play a leading role in the new AI platform, Pandemic Preparedness Engine

:: Consensus reached among Korean government, National Assembly, international organisations and industry to expand AI-enabled Health ODA

*News*

**[CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access](#)**

2 Feb 2026

:: Samsung Biologics becomes latest organisation to join CEPI's Vaccine Manufacturing Facility Network - a globally distributed manufacturing ecosystem capable of producing vaccines at speed and scale.

:: Project aims to establish a scalable, rapid manufacturing process for recombinant-protein vaccines.

:: In future pandemic situation, Samsung Biologics will provide CEPI with guaranteed access to up to potentially 50 million vaccine doses and one billion doses of drug substance.

*News*

**[Preparing today for tomorrow's Lassa fever vaccines](#)**

2 Feb 2026

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 07 Feb 2026]

<https://cioms.ch/>

*News; Publications; Events*

**[Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT](#)**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences. Deadline to submit your comments is 13 March 2026.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [07 Feb 2026]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases Initiative** [07 Feb 2026]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [07 Feb 2026]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [07 Feb 2026]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [07 Feb 2026]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [07 Feb 2026]

<http://www.euvaccine.eu/>

*News*

06 Feb 2026

**[A 4-dose RTS,S malaria vaccine schedule provides higher protection against severe malaria than a 3-dose schedule.](#)**

*The MVPE-CC consortium contributed key evidence reviewed in a joint session of the WHO's Strategic Advisory Group of Experts on Immunisation (SAGE) and Malaria Policy Advisory Group (MPAG) held in September 2025 for considerations of malaria vaccination schedules in perennial settings. The conclusions and recommendations of the SAGE and MPAG were published in the latest issue of the Weekly Epidemiological Record (No 49, 5 December 2025).*

**Fondation Merieux** [07 Feb 2026]

<http://www.fondation-merieux.org/>

*Actualités*

*No new digest content identified.*

**Gates Medical Research Institute** [07 Feb 2026]

<https://www.gatesmri.org/news>

*The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.*

*News: Articles and Publications*

*No new digest content identified.*



**Gavi** [to 07 Feb 2026]

<https://www.gavi.org/>

*News Releases*

4 February 2026

**Preventive cholera vaccination resumes as global supply reaches critical milestone**

**GE2P2 Global Foundation** [07 Feb 2026]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements/Digests*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 06 Feb 2026](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

**GHIT Fund** [07 Feb 2026]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

February 3, 2026

**Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai**

**Global Fund** [to 07 Feb 2026]

<https://www.theglobalfund.org/en/news/>

*News Releases*

04 February 2026

**Global Fund Launches Process to Select New Executive Director**

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has formally launched the process to select its next Executive Director for a four-year term starting from 2027.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [07 Feb 2026]

<https://www.glopid-r.org/>

*News & Events*

*No new digest content identified.*

**Hilleman Laboratories** [07 Feb 2026]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [07 Feb 2026]

<https://www.hhmi.org/news>

*Press Room*

**Karolin Luger Receives 2026 Vilcek Prize in Biomedical Science**

February 02, 2026

**Human Immunome Project** [nee Human Vaccines Project] [07 Feb 2026]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [07 Feb 2026]

<https://www.iavi.org/>

*Press Releases, Features*

*Press Releases*

**IAVI announces first vaccinations in IAVI G004, a Phase 1 clinical trial of a promising HIV vaccine approach**

January 6, 2026

*Study will examine safety, immune response, and dose of three promising immunogens*

:: In 2024, 40.8 million people were living with HIV, and 1.3 million people newly acquired HIV

:: The IAVI/Scripps Research HIV vaccine development strategy aims to coach the immune system to produce broadly neutralizing antibodies that could provide broad protection against HIV

**INSERM** [07 Feb 2026]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 07 Feb 2026]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selected]*

Ongoing Public Consultations		^
>	Q3E EWG    Guideline for Extractables and Leachables	
>	E22 EWG    General Considerations for Patient Preference Studies	

<https://www.ich.org/page/public-consultations>

**ICRC** [to 07 Feb 2026]

<https://www.icrc.org/en/news>

*Latest press releases and statements*

06-02-2026

**ICRC president elected to a second term**

On 4 February 2026, the Assembly of the International Committee of the Red Cross (ICRC), the ICRC's supreme governing body, re-elected Mirjana Spoljaric to serve as president for a second four-year term.

**IFFIm** [07 Feb 2026]

<http://www.iffim.org/>

*Press Releases/Announcements*

**IFRC** [to 07 Feb 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press releases*

*No new digest content identified.*

**IPPS - International Pandemic Preparedness Secretariat** [07 Feb 2026]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [07 Feb 2026]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 07 Feb 2026]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News, Resources*

*No new digest content identified.*

**IVAC** [07 Feb 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [07 Feb 2026]

<http://www.ivi.int/>

*IVI News & Announcements*

**Korea to run landmark pandemic simulation exercise to strengthen outbreak readiness**

5 February 2026,

**Johns Hopkins Center for Health Security** [07 Feb 2026]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

February 5, 2026:

**Johns Hopkins Center for Health Security Commends Senators' New Bill to Create Federal Biotech Security Framework**

**Robert Wood Johnson Foundation** [to 07 Feb 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

*Latest News and Highlights*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 07 Feb 2026]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Indonesia*

**Responding to devastating flooding in Aceh after Cyclone Senyar**

Project Update 6 Feb 2026

*Syria*

**Helping care reach people in Daraya after years of war**

Project Update 5 Feb 2026

*South Sudan*

**South Sudan: Government forces bombarded MSF hospital in Lankien, Jonglei state**

Press Release 4 Feb 2026

*Mauritania*

**Mauritania: MSF provides care to Malian refugees fleeing immense violence**

Project Update 3 Feb 2026

**National Academy of Medicine** - USA [to 07 Feb 2026]

<https://nam.edu/programs/>

*News, Stories, Insights*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 07 Feb 2026]

<https://www.nationalacademies.org/newsroom>

*News*

**Neil H. Shubin Elected To Be Next National Academy of Sciences President; International Secretary, Councilors Also Chosen**

WASHINGTON — Neil H. Shubin, Robert R. Bensley Distinguished Service Professor of Organismal Biology and Anatomy and vice dean for academic advancement at the University of Chicago, has been

elected as the next president of the National Academy of Sciences. He will begin his five-year term on July 1, succeeding Marcia McNutt, who has served as the Academy's president since 2016...

### **National Academies Welcome Inaugural Cohort of Biotechnology Regulatory Fellowship Fellows**

*News Release* By Solomon Self

Last update February 2, 2026

WASHINGTON — The National Academies of Sciences, Engineering, and Medicine has announced the inaugural cohort of 10 fellows in its new Biotechnology Regulatory Fellowship Program, launched in 2025 to engage early-career professionals in developing the evidence basis needed to meet future regulatory challenges presented by novel products of biotechnology.

**PATH** [07 Feb 2026]

<https://www.path.org/media-center/>

*Newsroom [Selected]*

*No new digest content identified.*

**Sabin Vaccine Institute** [07 Feb 2026]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [07 Feb 2026]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Press Release*

### **UNAIDS strongly welcomes bold, new US funding package for HIV**

GENEVA, 5 February 2026—UNAIDS welcomes the signing into law of a bipartisan US\$ 5.88 billion spending package that reinforces the continued commitment and leadership of the United States in the global response to HIV.

US President Donald Trump signed the consolidated spending package into law on 3 February 2026 which allocates US\$ 4.6 billion to bilateral HIV support through the America First Global Health Strategy, US\$ 1.25 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria and US\$ 45 million to UNAIDS...

**UNICEF** [to 07 Feb 2026]

<https://www.unicef.org/media/press-releases>

*Press release* 04 February 2026

### **Preventive cholera vaccination resumes as global supply reaches critical milestone**

GENEVA/NEW YORK, 4 February 2026, – Global cholera vaccine supply has now increased to a level sufficient to allow the resumption of life-saving preventive campaigns for the first time in over three years, Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO) announced today. Mozambique is th...

**Unitaid** [07 Feb 2026]

<https://unitaid.org/>

*News releases*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [07 Feb 2026]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccine Confidence Project** [07 Feb 2026]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [07 Feb 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

[Vaccine Update Newsletter January 2026](#)

**Wellcome Trust** [07 Feb 2026]

<https://wellcome.org/>

*News. Opinion, Reports*

*Website not responding at inquiry.*

**The Wistar Institute** [to 07 Feb 2026]

<https://www.wistar.org/news/press-releases>

*Press Releases*

February 3, 2026

[\*\*Wistar Scientists Demonstrate First-Ever Single-Shot HIV Vaccine Neutralization Success\*\*](#)

The innovative approach could significantly shorten and simplify HIV vaccination protocols, making them more accessible worldwide

**World Bank** [to 07 Feb 2026]

<http://www.worldbank.org/en/news/all>

*News [Selected]*

*No new digest announcements identified.*

**WFPHA: World Federation of Public Health Associations** [07 Feb 2026]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest announcements identified.*

**World Medical Association [WMA]** [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest announcements identified.*

**World Organisation for Animal Health [OIE]** [07 Feb 2026]

<https://www.oie.int/>

*Press Releases, Statements*

*Joint Statement*

**Renewed Quadripartite Memorandum of Understanding regarding cooperation on One Health**

Published on 3 February 2026

Through the renewal of the Memorandum of Understanding (MoU) on One Health, the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH) reaffirm their shared commitment to advancing the implementation of the One Health approach...

Through this renewed Memorandum of Understanding, FAO, UNEP, WHO, and WOAH reaffirm their collective determination to reduce health risks and promote sustainable health outcomes for humans, animals, plants, ecosystems, and the wider environment worldwide. This renewed Memorandum of Understanding shall remain in force until 28 November 2030. The full text of the revised MoU and the letter of renewal are available: [MoU between FAO, UNEP, WHO, WOAH regarding cooperation on One Health](#)

.....  
.....

**ARM [Alliance for Regenerative Medicine]** [07 Feb 2026]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest announcements identified.*

**BIO** [07 Feb 2026]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [07 Feb 2026]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [07 Feb 2026]

<https://internationalbiotech.org/>

*News*

*No new digest announcements identified.*

**IFPMA** [07 Feb 2026]

<https://ifpma.org/>

*News & Resources*

*Statement 6 Feb 2026*



### **158th session of the WHO Executive Board (EB158): Reform of the global health architecture and the UN80 initiative**

On 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva. The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official...

*Statement 4 Feb 2026*

### **158th session of the WHO Executive Board: WHO's work in health emergencies**

We appreciate the opportunity to contribute to the discussions at EB158. WHO's work on strengthening emergency preparedness reflects a shared commitment to ensuring the world is better equipped for future health threats. We welcome this direction and the emphasis on clarity, coordination, and readiness. As EB158 documents highlight, WHO will now take on an expanded set of responsibilities...

*Statement 4 Feb 2026*

### **158th session of the WHO Executive Board (EB158): Draft updated global action plan on antimicrobial resistance**

On 4 February 2026, IFPMA delivered a statement on Agenda item 14 on the draft updated global action plan on antimicrobial resistance (AMR) at the 158th session of the WHO Executive Board. We welcome the timely update of the Global Action Plan on AMR (GAP), which provides a unique opportunity to take stock of progress...

*Statement 4 Feb 2026*

### **158th session of the WHO Executive Board (EB158): Harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector**

On 4 February 2026, IFPMA delivered a statement on Agenda item 15 on harmonization of regulatory approaches, governance, and standards for data, digital health, and artificial intelligence in the health sector at the 158th session of the WHO Executive Board in Geneva. Noting the work carried out by several multilateral institutions on digital health transformation,...

*Statement 4 Feb 2026*

### **158th session of the WHO Executive Board: Substandard and falsified medical products**

On 4 February 2026, IAPO delivered a statement on Agenda item 12 on substandard and falsified medical products at the 158th session of the WHO Executive Board on behalf of the Fight the Fakes Alliance, of which IFPMA is a member. The International Alliance of Patients' Organizations, on behalf of the Fight the Fakes Alliance,...

*Statement 3 Feb 2026*

### **158th session of the WHO Executive Board (EB158): Co-creating the Global Action Plan for rare diseases**

On 3 February 2026, IFPMA delivered a statement on Agenda item 9: Co-creating the Global Action Plan for rare diseases at the 158th session of the WHO Executive Board. IFPMA commends Member States and the WHO for implementing the 2025 WHA Resolution on Rare Diseases and strongly supports the prompt initiation of a Global Action...

**International Alliance of Patients' Organizations – IAPO** [07 Feb 2026]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

**An Open Letter ahead of the 158th WHO Executive Board and 79th World Health Assembly**

*Press and media* Tuesday, 3 February 2026

...discussions during the 158th WHO Executive Board meeting in February and the 79th World Health Assembly in May 2026 must lead to concrete commitments, actions and accountability on health data governance..

▪

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

#### **Constituency Statement: WHO's Executive Board Meeting 158 (February 2026)**

Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the needs of people living with or affected by NCDs, including reducing out-of-pocket costs and...

### **PhRMA** [07 Feb 2026]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....

.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

*We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.*

#### **AstraZeneca**

*Press Releases - No new digest announcements identified.*

#### **Bavarian Nordic**

*Latest News - No new digest announcements identified.*

#### **BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified.*

#### **Biological E**

*News - No new digest announcements identified.*

#### **BioNTech**

*Press Releases - No new digest announcements identified.*

#### **Boehringer**

*Press Releases - No new digest announcements identified.*

#### **CanSinoBIO**

*News - Website not responding at inquiry.*

#### **CIGB**

*Latest News - No new digest announcements identified.*

#### **CinnaGen**

*Recent News - No new digest announcements identified.*

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **CSL Sequirus**

News Releases - No new digest announcements identified.

## **Curevac**

News - Website now directs to BioNTech site

## **Dailchi Sankyo**

Press Releases - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media - No new digest announcements identified.

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **HIPRA**

Press releases - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

## **Merck**

News releases - No new digest announcements identified.

## **Nanogen**

News - No new digest announcements identified.

## **Novartis**

News

**[Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery](#)**

Feb 06, 2026

:: New facility will enable end-to-end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland

:: Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees

:: Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients

## **Novavax**

Press Releases - No new digest announcements identified.

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Samsung Biologics**

Latest News

Press Releases Feb 4, 2026

[\*\*CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access\*\*](#)

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute**

News & Announcements - No new digest announcements identified.

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

**Sinovac**

Press Releases - No new digest announcements identified.

**SK Biosciences**

Press Releases

[\*\*SK bioscience Strengthens Global Pandemic Preparedness through Participation in Korea's "100 Days Mission" Simulation Exercise\*\*](#)

2026.02.05

[\*\*SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute\*\*](#)

2026.02.03

:: SK to advance novel early-clinical stage RSV preventive monoclonal antibody in-licensed from Gates Medical Research Institute

:: Exclusive rights to commercialize the product in high income countries with non-exclusive supply in India and Gavi-supported countries in addition to charitable Global Access commitments

:: Plans to advance large scale manufacturing process development to enable affordable supply to low- and middle-income countries.

**Takeda**

Newsroom - No new digest announcements identified.

**Valneva**

Press Releases

February 3, 2026

[\*\*Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®\*\*](#)

**WestVac Biopharma**

Media - No new digest announcements identified.

**Zhifei Longcom**, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

**Contents** [*click to move among sections*]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

#### **Aging Is Bad for You?**

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

### **American Journal of Human Genetics**

Feb 05, 2026 Volume 113 Issue 2 p235-400

<https://www.cell.com/ajhg/current>

**This month in *The Journal***

Paul W. Hook, Alyson B. Barnes

The current biotechnology industry is characterized by intense competition. Although this competition can drive innovation and increased investment, too much competition can prevent collaboration and potentially foster a culture in which data and methods are stockpiled and guarded. The United States Federal Trade Commission (FTC) advances government policies that promote free and open competition and challenges anticompetitive business practices. In this issue, Rashid et al. provide an overview of recent policy changes at the FTC surrounding competition and innovation in human genetics and genomics, using the Illumina and Grail merger in 2021 as a case study.

*Perspective*

**Competition in human genetic technologies: The current US legal landscape**

Abdulai I. Rashid, Nicole A. Rincon, Nathan Rihani, Jennifer K. Wagner

*Open Access*

Here, we offer a perspective on the US legal landscape regarding the promotion of competition, with specific attention given to the human genetics and genomics industry. We highlight current policy on mergers, non-competition agreements, and exclusive dealings and use Illumina and Grail as a case study.

**American Journal of Infection Control**

February 2026 Volume 54 Issue 2 p107-240

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

February 2026 Volume 70 Issue 2

<https://www.ajpmonline.org/current>

[Reviewed earlier]

**American Journal of Public Health**

January 2026 116(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 114 (2026): Issue 2 (Feb 2026)

<https://www.ajtmh.org/view/journals/tpmd/114/2/tpmd.114.issue-2.xml>

*Articles*

**Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil**

Karin Regina Luhm, et al.

Research Article

DOI: <https://doi.org/10.4269/ajtmh.24-0837> Page(s): 338–347

**Factors Associated with Human Papillomavirus Vaccination Uptake Among Adolescent Girls in Uganda**

Stanley Ggingo, Susan Obore, Miton Musaba, Julius Wandabwa, and Paul Kiondo  
Research Article  
DOI: <https://doi.org/10.4269/ajtmh.25-0503> Page(s): 355–359

### **Annals of Internal Medicine**

January 2026 Volume 179, Issue 1  
<https://www.acpjournals.org/toc/aim/current>  
[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 351 February 2026  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/351/suppl/C>  
[New issue; No digest content identified]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 07 Feb 2026)  
[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 07 Feb 2026)  
[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>  
(Accessed 07 Feb 2026)

#### **[Forecasting and quantifying the role of vaccination strategies in the 2025 Texas measles outbreak: a modeling and time series analysis approach](#)**

Chidozie W. Chukwu  
Research Open access 07 February 2026

#### **[Acceptability of the Ebola vaccine in the sub-Saharan African population: A systematic review and meta-analysis](#)**

Beni Matangi, Placide Matondo, Ben Bepouka  
Systematic Review Open access 06 February 2026

#### **[Factors associated with tetanus, diphtheria and pertussis \(Tdap\) vaccination acceptance among pregnant women: a cross-sectional study](#)**

Nurhasifah Abd Aziz, Nor Afiah Mohd Zulkefli, Zainab Hananah Abang Abdullah  
Original Paper Open access 02 February 2026

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>  
(Accessed 07 Feb 2026)  
[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 07 Feb 2026)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 07 Feb 2026)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 07 Feb 2026)

*Articles*

[Association between COVID-related health literacy and vaccine acceptance: results of a nationwide cross-sectional study in Hungary](#)

Yusuf Elisha Karu, Gabriella Mátyás, Éva Bíró

Research Open access 07 February 2026

[COVID-19 vaccine acceptability and determinants of hesitancy among adults in Lagos, Nigeria](#)

Chioma Ibenye-Ugbala, Ifeoma Peace Okafor, Aisha Abdulkareem

Research Open access 06 February 2026

[Trust in science, knowledge and risk perception as predictors of COVID-19 vaccination: application of an extended Theory of Planned Behavior model in Hungary](#)

Marianna Kopasz, Zsófia Papp, Ildikó Husz

Research Open access 03 February 2026

[Ignorance is not bliss: the impact of sources of information on HPV vaccination knowledge, attitudes, and intentions among unvaccinated young adults in Israel](#)

Sophie Lazar, Jacob Bornstein, Michael Edelstein

Research Open access 02 February 2026

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 07 Feb 2026)

[No new digest content identified]

## **BMJ Evidence-Based Medicine**

December 2025 - Volume 30 - 6

<https://ebm.bmj.com/content/30/6>

[Reviewed earlier]

## **BMJ Global Health**



January 2026 - Volume 11 - 1  
<https://gh.bmj.com/content/11/1>  
[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - December 2025  
<https://thebulletin.org/magazine/2025-12/#post-heading>  
[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 104, Number 2, February 2026, 61-136

*Articles*

[\*\*Towards a shared vision for research on evidence-informed policy-making.\*\*](#)

Kolt B, Kuchenmüller T, Mandil A, Boaz A, Patiño-Lugo DF, Reeder JC, Oliver K, Terry RF, Charnaud SC, Sharma T, Pangestu TE.

### **Cell**

Jan 22, 2026 Volume 189 Issue 2 p343-696  
<https://www.cell.com/cell/current>  
[Reviewed earlier]

### **Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4  
<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>  
[Reviewed earlier]

### **Child Care, Health and Development**

Volume 52, Issue 1 January 2026  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 119, Issue 2 Pages: 281-563 February 2026  
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>  
[Reviewed earlier]

### **Clinical Therapeutics**

January 2026 Volume 48 Issue 1 p1-134  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 6, December 2025  
<https://journals.sagepub.com/toc/ctja/22/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 161 February 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/161/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 8, Issue 6 / December 2025

<https://www.liebertpub.com/toc/crispr/8/6>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2026 - Volume 39 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Cytotherapy**

March 2026 Volume 28 Issue 3

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 25, Issue 4 Pages: 253-323 December 2025  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 35, Issue 5, 2025  
<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>  
[Reviewed earlier]

### **Development Policy Review**

Volume 44, Issue 1 January 2026  
<https://onlinelibrary.wiley.com/toc/14677679/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025  
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>  
[Reviewed earlier]

### **Disasters**

Volume 50, Issue 1 January 2026  
<https://onlinelibrary.wiley.com/toc/14677717/current>  
[Reviewed earlier]

### **eBioMedicine**

Volume 122 December 2025  
<https://www.sciencedirect.com/journal/ebiomedicine/vol/121/suppl/C>  
[Reviewed earlier]

### **EMBO Reports**

Volume 27, Issue 1 January 2026  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 32, Number 1—January 2026  
<http://wwwnc.cdc.gov/eid/>  
[New issue; No digest content identified]

### **Epidemics**

Volume 53 December 2025  
<https://www.sciencedirect.com/journal/epidemics/vol/53/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 48, Issue 1 Pages: 1-48 January–February 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Research and pregnant women • Considerations for informed consent***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 39 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 6, December 2025

<https://academic.oup.com/eurpub/issue/35/6>

[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

January/February 2026 Volume 105, Number 1

<https://www.foreignaffairs.com/issues/2026/105/1>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

***The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities***

[Reviewed earlier]

### **Frontiers in Genetics**

<https://www.frontiersin.org/journals/genetics>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Frontiers in Genome Editing**

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Gene Therapy – Nature**

Volume 32 Issue 6, December 2025

<https://www.nature.com/gt/volumes/32/issues/6>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 28, Issue 1 January 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/1>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Global Health Action**

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

*Study design article*

*Method*

**[Public opinion survey on heritable human genome editing in South Africa: a study protocol](#)**

Siddharthiya Pillay & Donrich Thaldar

Article: 2598132

Published online: 02 Jan 2026

### **Global Health: Science and Practice (GHSP)**

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 07 Feb 2026]

[No new digest content identified]

## **Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 07 Feb 2026]

### **[U.S. withdrawal from WHO and aid programs: implications and opportunities for Africa's global health security](#)**

Justin Onyebuchi Nwofe, Emmanuel Adewale Ojo, Babatope O. Adebisi

*Comment* Open access 04 February 2026 Article: 19

### **[From PHEIC to PHECs: reclaiming Africa's agency in global health security governance](#)**

Nelson Aghogho Evaborhene

*Comment* Open access 04 February 2026 Article: 18

## **Health and Human Rights**

Volume 27, Issue 2, December 2025

<https://www.hhrjournal.org/volume-27-issue-2-december-2025/>

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 20 - Issue 4 - October 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 10, November 2025

<https://academic.oup.com/heapol/issue/40/10>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Human Gene Therapy**

Volume 36, Issue 23-24 / December 2025

[https://www.liebertpub.com/toc/hum/36/2\\_3-24](https://www.liebertpub.com/toc/hum/36/2_3-24)

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

### **Immunity**

Jan 13, 2026 Volume 59 Issue 1 p1-228

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **International Health**

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 12 (2025): December 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/131>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 54, Issue 5, October 2025

<https://academic.oup.com/ije/issue/54/5>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 18, Issue 5 4 November 2025

<https://www.emerald.com/ijhrh/issue/18/5>

[Reviewed earlier]

### **JAMA**

February 3, 2026, Vol 335, No. 5, Pages 383-470

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

#### **Interim Safety of RSVpreF Vaccination During Pregnancy**

Ashley I. Michnick, PharmD, PhD; Sarah C. MacDonald, ScD; Austin Cosgrove, BS; et al.

*JAMA*. 2026;335(5):456-459. doi:10.1001/jama.2025.23452

This interim analysis of an ongoing retrospective cohort study uses data from 5 US health plans to assess safety of a bivalent prefusion F subunit–based respiratory syncytial virus (RSV) vaccine administered during pregnancy during the first full RSV season after US Food and Drug Administration approval (from September 22, 2023, through June 14, 2024).

### **JAMA Health Forum**

January 2026, Vol 7, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

January 2026, Vol 180, No. 1, Pages 3-120

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JBIR Evidence Synthesis**

January 2026 - Volume 24 - Issue 1

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

February 2026 Volume 78 Issue 2 p203-370

<https://www.jahonline.org/current>

[Reviewed earlier]



### **Journal of Artificial Intelligence Research**

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Bioethical Inquiry**

Volume 22, Issue 3 September 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-3>

[Reviewed earlier]

### **Journal of Community Health**

Volume 50, Issue 6 December 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-6>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

February 2026 - Volume 80 - 2

<https://jech.bmj.com/content/80/2>

[New issue: No digest content identified]

### **Journal of Evidence-Based Medicine**

Volume 18, Issue 4 December 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 21, Issue 2 (2025)  
<http://www.tandfonline.com/toc/rjge20/current>  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 4, November 2025  
<https://muse.jhu.edu/issue/55986>  
*Table of Contents*  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 5 October 2025  
<https://link.springer.com/journal/10903/volumes-and-issues/27-5>  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 24, Issue 1 (2026)  
<https://www.tandfonline.com/toc/wimm20/current>  
[New issue: No digest content identified]

**Journal of International Development**

Volume 38, Issue 1 Pages: 1-191 January 2026  
<https://onlinelibrary.wiley.com/toc/10991328/current>  
[Reviewed earlier]

**Journal of Law, Medicine & Ethics**

Volume 53 - Issue 3 - Fall 2025  
<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>  
***Public Health, Markets, and Law***  
[Reviewed earlier]

**Journal of Medical Ethics**

February 2026 - Volume 52 - 2  
<http://jme.bmj.com/content/current>  
*Extended essays*  
[A global redistributive auction for vaccine allocation](#) (14 June, 2024)  
Aksel Braanen Sterri, Peder Skjelbred

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 3 (2025)  
<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 288 January 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/288/suppl/C>

[New issue; No digest content identified]

### **Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

November/December 2025 - Volume 31 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Public Health Policy**

Volume 46, Issue 4 December 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-4>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

Volume 22, Issue 233 1 December 2025

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 33, Issue 1, January 2026

<https://academic.oup.com/jtm/issue>

*Editorial*

[\*\*Rethinking WHO's Japanese encephalitis vaccination policies: why age limits no longer match outbreak reality\*\*](#)

AbdulRahman A Saied and others

### **The Lancet**

Feb 07, 2026 Volume 407 Number 10528 p547-648

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

[\*\*Venezuela: health beyond the political turmoil\*\*](#)

The Lancet

### **The Lancet Child & Adolescent Health**

Feb 2026 Volume 10 Number 2 p71-146, e4-e9

<https://www.thelancet.com/journals/lanchi/issue/current>

[New issue; No digest content identified]

### **Lancet Digital Health**

Dec 2025 Volume 7 Number 12

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Feb 2026 Volume 14 Number 2 e173-e310

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

#### **[7-year trend of timely hepatitis B birth dose vaccination coverage in The Gambia: a retrospective, population-based analysis](#)**

Gibril Ndow, et al.

According to WHO and UNICEF, Africa has the lowest coverage (18%) of timely (within the first 24 h) hepatitis B birth dose (HepB-BD) vaccination worldwide. To eliminate hepatitis B by 2030, 90% vaccination coverage is required. Experiences from The Gambia, the first African country to adopt HepB-BD vaccination in 1990, could guide HepB-BD implementation and scale-up in Africa. We aimed to assess the trend of, and barriers to, timely HepB-BD vaccination coverage over a 7-year period in The Gambia... 30 years after the adoption of HepB-BD in The Gambia, the rate of vaccination coverage remains low and was significantly affected by the COVID-19 pandemic, highlighting the challenges for its implementation.

### **Lancet Infectious Diseases**

Feb 2026 Volume 26 Number 2 p111-212, e77-e131

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Feb 2026 Volume 11 Number 2 e69-e136

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

### **Lancet Respiratory Medicine**

Feb 2026 Volume 14 Number 2 p99-186, e9-e18

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

### **Maternal and Child Health Journal**

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>

[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 46 Issue 1, January 2026

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue S1 Pages: 1-462 November 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

***Special Issue: Mental Health and Substance Use Challenges Facing the United States: What Can State Policy Makers Do***

[New issue; No digest content identified]

### **Molecular Therapy**

Feb 04, 2026 Volume 34 Issue 2 p645-1292

<https://www.cell.com/molecular-therapy/current>

*Meeting report*

**[Navigating new horizons: Key insights from ASGCT's 2025 Policy Summit](#)**

Allison M. Bradbury

The 2025 American Society of Gene and Cell Therapy (ASGCT) Policy Summit<sup>1</sup> convened industry leaders, regulators, patient advocates, and policymakers in September at a pivotal moment for the cell and gene therapy (CGT) field. As one of the session moderators and an attendee for the event, I experienced firsthand the in-depth discussions on creative opportunities to accelerate innovation and expand patient access through collaboration and strategic adaptation.

### **Nature**

Volume 650 Issue 8100, 5 February 2026

<https://www.nature.com/nature/volumes/650/issues/8100>

*Editorial* 04 Feb 2026

**[Now is not the time to defund human fetal tissue research](#)**

Hindering studies involving fetal tissue will impede the development of the alternatives intended to replace it, while slowing the search for new medicines.

### **Nature Biotechnology**

Volume 44 Issue 1, January 2026

<https://www.nature.com/nbt/volumes/44/issues/1>

[New issue; No digest content identified]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 07 Feb 2026)

[Reviewed earlier]

### **Nature Genetics**

Volume 58 Issue 1, January 2026

<https://www.nature.com/ng/volumes/58/issues/1>

[New issue; No digest content identified]

### **Nature Human Behaviour**

Volume 10 Issue 1, January 2026

<https://www.nature.com/nathumbehav/volumes/10/issues/1>

Article 10 Sep 2025

**[Interventions to reduce vaccine hesitancy among adolescents: a cluster-randomized trial](#)**

In this randomized controlled trial, Baudouin et al. find that both pedagogical activities and a chatbot improve ninth graders' attitudes and knowledge about vaccination, offering scalable ways to counter vaccine hesitancy in adolescents.

N. Baudouin, S. de Rouilhan, H. Mercier

**Nature Medicine**

Volume 32 Issue 1, January 2026

<https://www.nature.com/nm/volumes/32/issues/1>

Article Open Access 06 Jan 2026

**[Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial](#)**

The R21/Matrix-M vaccine, but not the ME-TRAP vaccine, was protective against intradermal challenge with *Plasmodium falciparum* sporozoites, while neither was protective against direct venous inoculation, potentially explaining previously observed differences in protection.

Melissa C. Kapulu, Francesca Orenge, Philip Bejon

**Nature Reviews Drug Discovery**

Volume 25 Issue 1, January 2026

<https://www.nature.com/nrd/volumes/25/issues/1>

[New issue; No digest content identified]

**Nature Reviews Genetics**

Volume 27 Issue 1, January 2026

<https://www.nature.com/nrg/volumes/27/issues/1>

Editorial 15 Dec 2025

**[Microbial ecology and evolution in the genomics era](#)**

Microbial genomics has yielded transformative insights into the ecology and evolution of microorganisms. *Nature Reviews Genetics* presents a Focus issue that explores how genomic approaches reveal microbial dynamics across ecological and evolutionary contexts.

**Nature Reviews Immunology**

Volume 26 Issue 2, February 2026

<https://www.nature.com/nri/volumes/26/issues/2>

Review Article 12 Sept 2025

**[Targets of protective immunity and opportunities in hepatitis C virus vaccine development](#)**

Despite the advances in hepatitis C treatment, a prophylactic vaccine is still not available and will be needed to control and eliminate hepatitis C virus (HCV) infections globally. In this Review, the authors examine the current understanding of protective immune responses and describe the challenges, prospects and new technologies in HCV vaccine development.

Seung Bum Park, Paul Zimmer-Harwood, T. Jake Liang

**New England Journal of Medicine Volume**

Volume 394 No. 6 February 5, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

### **NEJM Evidence**

Volume 4 No. 12 December 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Pediatrics**

Volume 157, Issue 1 January 2026

<https://publications.aap.org/pediatrics/issue/157/1>

[New issue; No digest content identified]

### **PharmacoEconomics**

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 07 Feb 2026)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 07 Feb 2026)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 07 Feb 2026)

**[Policies and strategies for HPV vaccination schedule completion in immunocompromised girls, including girls living with HIV: Qualitative insights from Eswatini, Malawi, and Uganda](#)**

Emily E. Crawford, Tosin F. Ajayi, Immaculate Ampeire, Michael Baganizi, Mike N. Chisema, Bridget C. Griffith, Lorraine Kabunga, Thuli Magagula, Lisa-Rufaro Marowa, Akachi E. Mbogu, Nobuhle Mthethwa, Stella Namutebi, Bhekiwe Shongwe, Timothy Tchereni, Frehiwot Birhanu, Xolisiwe Dlamini, Fredrick Luwaga, Sonali Patel

Research Article | published 03 Feb 2026 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0004688>

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 07 Feb 2026)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 07 Feb 2026)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 07 Feb 2026]

#### **[The cost and cost drivers of delivering COVID-19 vaccines in low- and middle-income countries: a bottom-up costing study of rollouts in seven countries](#)**

Flavia Moi, Văn Minh Nguyễn, Rachel Archer, Tozé Namalela, Christina Banks, Tarek Hossain, Afroja Yesmin, Cathbert Tumusiime, Charlotte Muheki, Kelsey Vaughan, Elise Smith, Rafael Deo Estanislao, Pierre Z. Akilimali, Hong Thi Duong, Chien Chinh Vien, Amélia Dipuve, Pedro Marizane Pota, Monjurul Islam, Paul Kiggundu, Okello Ayen Daniel, Sarah De Los Reyes, Jeremie de Guzman, Christelle Cuevas, Primrose Nakazibwe, Carl Schutte, Minh Van Hoang, Laura Boonstoppel

Research Article | published 02 Feb 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0341964>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

February 3, 2026 vol. 123 no. 5

<https://www.pnas.org/toc/pnas/123/5>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 4, Issue 11, November 2025

<https://academic.oup.com/pnasnexus/issue/4/11>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 40 - Issue 6 - December 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]



**Preventive Medicine**

Volume 203 February 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/203/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

Volume 293, Issue 2063 January 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

**Public Health**

Volume 249 December 2025

<https://www.sciencedirect.com/journal/public-health/vol/249/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025

<https://journals.sagepub.com/toc/phrg/140/5-6>

[Reviewed earlier]

**Qualitative Health Research**

Volume 36 Issue 1, January 2026

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 22 Issue 1, January 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 07 Feb 2026]  
[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 46, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 07 Feb 2026]

[No new digest content identified]

## **Royal Society Open Science**

Volume 13, Issue 2 1 February 2026

<https://royalsocietypublishing.org/toc/rsos/current>

[New issue; No digest content identified]

## **Science**

Volume 391| Issue 6785| 5 Feb 2026

<https://www.science.org/toc/science/current>

*Policy Forum*

### **Biological data governance in an age of AI**

BY Doni Bloomfield, et al.

05 Feb 2026: 558-561

*Abstract*

Scientists are making rapid progress in developing artificial intelligence (AI) models trained on biological data and in combining these biological models with general-purpose AI reasoning models and AI agents. After the 50th anniversary Asilomar Conference, an international group of more than 100 researchers endorsed an entreaty to prevent the use of these increasingly capable AI systems for “deliberately harmful applications such as bioweapons development” ([1](#)). [T.V.I., M.J.I., R.B.A., and J.P. joined that entreaty.] Expanding on the entreaty’s call for a system of data access control, we propose that governments, life-science funders, and other organizations impose tailored access restrictions on a narrow set of pathogen data that pose particular AI-related misuse risks. Unfettered access to data has generally served science and society well and should be preserved in almost all domains. Governments should thus regularly reassess the narrow restrictions we propose with the aim of refining them.

## **Science and Engineering Ethics**

Volume 31, Issue 6 December 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-6>  
[Reviewed earlier]

### **Science Translational Medicine**

Volume 18| Issue 835| 4 Feb 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Social Science & Medicine**

Volume 386 December 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 07 Feb 2026]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 68 November–December 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/68/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 31, Issue 1 Pages: 1-111 January 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

### **Vaccine**

Volume 73 15 February 2026

<https://www.sciencedirect.com/journal/vaccine/vol/73/suppl/C>

*Discussion*

**[Mpox vaccines: an urgent equity imperative](#)**

Yap Boum, Charles U. Ibeneme, Sheillah Nsasiirwe, Rose Nakame, ... Jean Kaseya

Article 128158

*Discussion*

**[Strengthening immunization and health systems to counter effects of climate change](#)**

Zulfiqar A. Bhutta, Christopher Wolff, Mickey Chopra, Francesco Checchi, ... Ephrem Tekle Lemango  
Article 128168

*Review article Open access*

**[Enablers and barriers to participation in vaccine trials: a narrative synthesis](#)**

Nadia Daniel, Christine Smith, Nasima Miah, Carol Akroyd, ... Maheshi N. Ramasamy  
Article 128183

*Research article Open access*

**[Vaccine hesitancy among older adults, urban indigenous and newcomers in Canada: A qualitative comparative study](#)**

Éliane Miron, Chantal Sauvageau, Eve Dubé, Maryline Vivion  
Article 128143

*Research article Abstract only*

**[Assessing vaccination coverage and antibody levels for measles, pertussis, and tetanus in Boende, DR Congo: Implications for maternal and child health](#)**

Maha Salloum, Leen Vandermosten, Tafadzwa Maseko, Solange Milolo, ... Patrick Mitashi  
Article 128083

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 07 Feb 2026]

*Open Access Review*

**[A Scoping Review of Influences on HPV Vaccine Uptake in the Rural US](#)**

by Sherri Sheinfeld Gorin, Rebecca Hyman, Courtney Olson, Elizabeth Amber Fournier, Kaitlyn Yang, Diana Hanko and HPV Review Working Group

Vaccines 2026, 14(2), 156; <https://doi.org/10.3390/vaccines14020156> - 5 Feb 2026

*Abstract*

The human papillomavirus (HPV) is the leading cause of cervical and oropharyngeal cancers. Vaccination can prevent over 90% of HPV-attributed cancers. Rural populations are less likely to initiate and complete HPV vaccinations than urban. The primary objective of this paper is to systematically [...]

**Value in Health**

February 2026 Volume 29 Issue 2 p175-346

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

**World Medical Journal – Official Journal of The World Medical Association**

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

**World Development**

Volume 200 April 2026

<https://www.sciencedirect.com/journal/world-development/vol/200/suppl/C>

[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

### ***Pre-Print Servers***

#### **arXiv**

<https://arxiv.org/>

[Accessed 07 Feb 2026]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

arXiv:2601.22621 [pdf, other]

#### **[Ethical Risks of Large Language Models in Medical Consultation: An Assessment Based on Reproductive Ethics](#)**

Hanhui Xu, Jiacheng Ji, Haoan Jin, Han Ying, Mengyue Wu

...As large language models (LLMs) are increasingly used in healthcare and medical consultation settings, a growing concern is whether these models can respond to medical inquiries in a manner that is ethically compliant--particularly in accordance with local ethical standards. To address the pressing need for comprehensive research on reliability and safety, this study systematically evaluates LLM performance in answering questions related to reproductive ethics, specifically assessing their alignment with Chinese ethical regulations.

#### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 07 Feb 2026]

*[Filter: All articles]*

Research Article metrics

#### **[Editorial Practices of African Journals: A Qualitative Analysis from Kenya, Ethiopia, Nigeria, and Mozambique](#)**

Patrick Amboka, Daniel Krugman, Abel Simiyu, H Kariuki, Benard Ondiek, Nosa Orobato, Emmy Igonya, Alphonsus Neba, Marta Vicente-Crespo, Julius Kiriimi Sindi

Funder - Gates Foundation

PUBLISHED 04 Feb 2026

The key structural issues on editorial practices among African journals established by the study included adherence to internationally accepted editorial practices on peer review decision-making and challenges in implementing measures of transparency and rigor. Some of the underlying factors affecting African journal editorial practices that were highlighted included financial constraints, challenges in peer review, challenges in maintaining editorial integrity, and challenges in technological

and digital infrastructure. African journals also face challenges of credibility and trustworthiness among authors. Participants outlined how the longstanding neglect of African journals and lack of funding have created cultures of editorial mismanagement, publishing inconsistency, and other logistical issues, all of which contribute to perceptions of African journals as inferior to Northern ones.

## **medRxiv**

<https://www.medrxiv.org/content/early/recent>

[Accessed 07 Feb 2026]

[Filter: All articles]

### **Impact of Rotavirus Vaccine on Malnutrition Among Children in India-Breaking Vicious Cycle of Diarrhea: A Cross-Sectional Analytical Study**

Ajay Kumar Verma, Pritu Dhalaria, Pawan Kumar, Sanjay Kapur, Pretty Priyadarshini, Ajeet Kumar Singh, Kapil Singh, Bhupendra Tripathi, Arindam Ray

medRxiv 2026.02.05.26345714; doi: <https://doi.org/10.64898/2026.02.05.26345714>

### **Perspectives of HIV policy makers and program implementers regarding the design and utilization of HIV surveillance systems in Sub-Saharan African countries experiencing a declining HIV epidemic: a qualitative study**

Victor Mwapasa, Fumbani Chigawa, Chikondi Mwapasa, Marriot Nliwasa, Takondwa Charles Msosa, Jeffrey W. Imai-Eaton, Beth A Tippet Barr

medRxiv 2026.02.05.26345633; doi: <https://doi.org/10.64898/2026.02.05.26345633>

### **Plans to Vaccinate Children Against COVID-19 Among Families Experiencing Homelessness and Other Families in Seattle, WA, October 2020-May 2021**

Constance E Ogokeh, Kinda Zureick, Julia H Rogers, Sarah N Cox, Amy C Link, Anne Emanuels, Janet Englund, James P Hughes, Timothy M Uyeki, Helen Y Chu, Emily Mosites, Melissa A Rolfes

medRxiv 2026.02.05.26344476; doi: <https://doi.org/10.64898/2026.02.05.26344476>

### **Determinants of Completeness and Timeliness of Pneumococcal Conjugate Vaccine Immunization in Yogyakarta, Indonesia: A Cross-Sectional Study**

Noorkhalisah Noorkhalisah, Risalia Reni Arisanti, Solikhin Dwi Ramtana, Mei Neni Sitaresmi

medRxiv 2026.02.03.26345526; doi: <https://doi.org/10.64898/2026.02.03.26345526>

### **Quantifying the contribution of Oral Cholera Vaccine to global health through tech-transfers and WHO stockpile deployment since its inception: a modeling study**

Jung-Seok Lee, Wongyeong Choi, Florian Marks, John D. Clemens, Jerome H. Kim, Julia Lynch

medRxiv 2026.02.02.26345439; doi: <https://doi.org/10.64898/2026.02.02.26345439>

### **A Cross-Sectional Study of COVID-19 Vaccine Hesitancy and Behaviours among People Living with HIV in British Columbia**

Anne Ejiegbu, Batoul Shariati, Jonathan Little, Mario Brondani

medRxiv 2026.01.31.26345295; doi: <https://doi.org/10.64898/2026.01.31.26345295>

### **A Decade of Progress: Description of Ebola Vaccination Strategy and its Associated Factors in Sierra Leone**

Desmond M. Kangbai, Edwin N. Sesay, Nella Clemens-Kangbai, Hassan Benya, Peter Bai James, Henry Carter, Andrew K. Kemoh, Sallu Lansana, Edna G. Samuels, Mohamed T. M. Kallay, Nelson Mandela Kargbo, Jia Kangbai, Francis Moses

medRxiv 2026.01.28.26345081; doi: <https://doi.org/10.64898/2026.01.28.26345081>

## **Impact of armed conflict on measles surveillance and zero-dose vaccination status in Tigray, Ethiopia, 2018 - 2024**

Habtamu Milkias Wolde, Youngoh Bae, Ali Raza, Seung Won Lee

medRxiv 2026.01.29.26345160; doi: <https://doi.org/10.64898/2026.01.29.26345160>

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 07 Feb 2026]

[No new digest content identified]

\* \* \* \*

### **Think Tanks**

**Brookings** [to 07 Feb 2026]

<http://www.brookings.edu/>

*Research, Events*

*Commentary*

**Redefining 'lifesaving': Prioritizing mental health, child protection, and education in Gaza**

Sweta Shah

February 5, 2026

:: Standard humanitarian response prioritizes food, water, shelter, and health care first, with mental health, child protection, and education addressed later. This "basic needs first" framework fails for children in protracted crises such as the one in Gaza.

:: For children, "saving a life" means more than biological survival. It means preserving the capacity for healthy development, learning, emotional regulation, and social connection.

:: Mental health, child protection, and education specialists must deploy alongside physical health and nutrition teams, not as a second wave. Donors, humanitarian groups, and governments all have a role to play in making this a reality.

**Center for Global Development** [07 Feb 2026]

<https://www.cgdev.org/>

*All Research*

*BRIEF*

**A Radically Simplified Global Fund to Meet the Moment**

Janeen Madan Keller et al.

February 05, 2026

*Key messages*

:: The Global Fund faces an increasingly difficult set of imperatives: it must sustain core HIV, tuberculosis, and malaria programs and invest strategically in potentially transformative innovations, all while confronting funding cuts and responding to calls for reform.

:: We propose "radical simplification" shifts across three dimensions to safeguard impact, stretch scarce resources, and enable reform:

[1] The Global Fund should concentrate resources in fewer countries where need is greatest. By phasing out grant support in wealthier middle-income countries, the Global Fund could absorb budget cuts without reducing support in the poorest countries and most fragile contexts.

{2}The Global Fund should align financing more closely with country priorities by easing disease-specific earmarks. Countries should receive a consolidated financing envelope and be allowed and encouraged to flexibly allocate resources across the three diseases and supportive health system functions, while maintaining accountability for disease-specific outcome targets.

{3}The Global Fund should, where feasible, prioritize on-budget country-led delivery and leverage complementary resources from multilateral development banks, particularly for “health systems” support.

:: The Board should use the current moment as a leverage point to steer bold changes to the Global Fund’s model. We urge the Fund’s leadership—backed by Board approval—to operationalize the three shifts outlined above in differentiated ways across country contexts.

**Chatham House** [to 07 Feb 2026]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [07 Feb 2026]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 07 Feb 2026]

<https://www.csis.org/>

*Reports [Selected]*

*Website not responding at inquiry.*

**McKinsey Global Institute** [to 07 Feb 2026]

<https://www.mckinsey.com/mgi/overview>

*Featured Research*

*No new digest content identified.*

**ODI** [Overseas Development Institute] [to 07 Feb 2026]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 07 Feb 2026]

<https://www.pewresearch.org/>

*Latest Publications*

*No new digest content identified.*

**Rand** [to 07 Feb 2026]



<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 07 Feb 2026]  
<https://www.urban.org/research>  
*New Research Publications - Selected*  
*Public Comment*

**[Public Comment on the CDC's Proposed Extension of the PRAMS Data Collection](#)**  
February 5, 2026

**World Economic Forum** [to 07 Feb 2026]  
<https://agenda.weforum.org/press/>  
*Media [Selected]*  
*No new digest content identified.*

.....  
.....

### ***Public Consultations/Call for Inputs/Call for Papers***

#### **[Request for Information on Draft NIH Controlled-Access Data Policy and Proposed Revisions to NIH Genomic Data](#)**

NATIONAL INSTITUTES OF HEALTH (NIH) Notice Number: NOT-OD-26-023 **Response Date:**  
**March 18, 2026**

##### *Purpose*

The National Institutes of Health (NIH) is requesting public input on its proposal to establish harmonized and transparent policy requirements for protecting human participant research data. Specifically, NIH proposes (1) establishing policy requirements for which data should be controlled-access under NIH data sharing policies, and (2) revising the NIH Genomic Data Sharing Policy to simplify and harmonize requirements.

##### *Background*

NIH serves as the steward of a wide range of research data and continuously works to optimize open sharing with appropriate protections throughout the entire data lifecycle. Given its numerous established data policies, NIH is proposing a holistic update to its data policy framework to strengthen data protections, clarify requirements, and reduce duplicative burden. NIH is proposing a new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations. This proposed policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types. It also provides a standard set of expectations across NIH Institutes, Centers and Offices to promote maximal responsible human participant data sharing through controlled access while simultaneously responding to emergent privacy and security risks, including those outlined in the following security directives...

#### **[Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT](#)**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences.

Medicines are public health tools. With regard to the quality and transparency of the assessment of

their effectiveness and safety, they are increasingly subject to the expectations and requirements of patients, healthcare professionals and regulators. Those involved in the development and delivery of medicines must therefore take full account of the aforementioned paradigm shifts. Additionally, the arrival of novel therapeutic agents, such as gene therapy, biologics and mRNA vaccines, whose modes of action and interactions with living organisms have very little in common with those of the more traditional chemical medicines, has brought into question the classic elements of pharmacovigilance and pharmacoepidemiology, such as the dose–effect relationship, drug causation criteria and the determination of drug exposure.

CIOMS full [concept note on Pharmacoepidemiology for Public Health](#)

You are invited to review and comment on the draft report entitled *Realising the Potential of Pharmacoepidemiology for Public Health Decision-Making*. [Download the report here](#).

Please note that comments will only be considered when using the [template provided here](#). The **deadline to submit your comments is 13 March 2026**.

\* \* \* \*

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*